Ipsen SA (IPN) - Total Assets
Based on the latest financial reports, Ipsen SA (IPN) holds total assets worth €6.83 Billion EUR (≈ $7.99 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IPN net assets for net asset value and shareholders' equity analysis.
Ipsen SA - Total Assets Trend (2002–2024)
This chart illustrates how Ipsen SA's total assets have evolved over time, based on quarterly financial data.
Ipsen SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Ipsen SA's total assets of €6.83 Billion consist of 31.4% current assets and 68.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.5% |
| Accounts Receivable | €697.20 Million | 10.8% |
| Inventory | €285.50 Million | 4.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.52 Billion | 39.1% |
| Goodwill | €699.50 Million | 10.9% |
Asset Composition Trend (2002–2024)
This chart illustrates how Ipsen SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Ipsen SA market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ipsen SA's current assets represent 31.4% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2024, up from 0.2% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 42.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 39.1% of total assets.
Ipsen SA Competitors by Total Assets
Key competitors of Ipsen SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Ipsen SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.98 | 1.14 | 1.06 |
| Quick Ratio | 1.79 | 0.98 | 0.89 |
| Cash Ratio | 1.02 | 0.29 | 0.00 |
| Working Capital | €1.40 Billion | €234.60 Million | €76.00 Million |
Ipsen SA - Advanced Valuation Insights
This section examines the relationship between Ipsen SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.47 |
| Latest Market Cap to Assets Ratio | 1.63 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | €6.44 Billion |
| Market Capitalization | $10.50 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Ipsen SA's assets above their book value (1.63x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Ipsen SA's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ipsen SA (2002–2024)
The table below shows the annual total assets of Ipsen SA from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €6.44 Billion ≈ $7.53 Billion |
+1.84% |
| 2023-12-31 | €6.32 Billion ≈ $7.39 Billion |
+12.75% |
| 2022-12-31 | €5.61 Billion ≈ $6.56 Billion |
+12.37% |
| 2021-12-31 | €4.99 Billion ≈ $5.83 Billion |
+15.71% |
| 2020-12-31 | €4.31 Billion ≈ $5.04 Billion |
+0.14% |
| 2019-12-31 | €4.31 Billion ≈ $5.04 Billion |
+27.52% |
| 2018-12-31 | €3.38 Billion ≈ $3.95 Billion |
+9.94% |
| 2017-12-31 | €3.07 Billion ≈ $3.59 Billion |
+26.76% |
| 2016-12-31 | €2.42 Billion ≈ $2.83 Billion |
+25.05% |
| 2015-12-31 | €1.94 Billion ≈ $2.27 Billion |
+13.12% |
| 2014-12-31 | €1.71 Billion ≈ $2.00 Billion |
+9.46% |
| 2013-12-31 | €1.57 Billion ≈ $1.83 Billion |
+0.27% |
| 2012-12-31 | €1.56 Billion ≈ $1.83 Billion |
-4.43% |
| 2011-12-31 | €1.63 Billion ≈ $1.91 Billion |
-2.67% |
| 2010-12-31 | €1.68 Billion ≈ $1.96 Billion |
+6.43% |
| 2009-12-31 | €1.58 Billion ≈ $1.84 Billion |
+0.45% |
| 2008-12-31 | €1.57 Billion ≈ $1.84 Billion |
+18.66% |
| 2007-12-31 | €1.32 Billion ≈ $1.55 Billion |
+8.95% |
| 2006-12-31 | €1.21 Billion ≈ $1.42 Billion |
+28.83% |
| 2005-12-31 | €942.51 Million ≈ $1.10 Billion |
+52.09% |
| 2004-12-31 | €619.71 Million ≈ $724.51 Million |
-6.94% |
| 2003-12-31 | €665.90 Million ≈ $778.50 Million |
+0.54% |
| 2002-12-31 | €662.33 Million ≈ $774.34 Million |
-- |
About Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more